Intrasynovial Digital Anesthesia in Trigger Finger

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorKevin Zuo

About this trial

Trigger finger is a common disease of the hand involving swelling and inflammation of the tendon which flexes a finger, causing catching, locking, and/or pain. Trigger finger is typically treated by hand surgeons with a steroid injection through the front/palm side of the hand into the area near the tendon (i.e., at the base of the affected finger). This steroid injection is often combined with a local anesthetic (numbing agent) to help reduce short-term pain from the injection. However, the front/palm side of the hand is known to be very sensitive, and the steroid injection can be quite painful as the needle pierces the front/palm skin.

To reduce the pain of steroid injections for trigger finger, a different approach involves performing the injection from the back/dorsal side of the hand, which is thought to be less sensitive (and therefore less painful) than the front/palm side of the hand. This technique is sometimes used and has been previously studied, but it is not clear if it can offer less injection-related pain than standard treatment.

Accordingly, this study will be comparing short-term injection-associated pain between front/palm side and back/dorsal side steroid injections for trigger finger. The study will also seek to understand what area of the hand is numbed by the anesthetic when doing a front/palm side injection versus a back/dorsal side injection of the hand. Overall, the investigators hypothesize that back/dorsal side injections will be less painful than front/palm side injections for trigger fingers and that the area of numbing from the anesthetic will be equivalent between both types of injections.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Be 18 years of age or older

Have a diagnosis of trigger finger (can be any of the 5 digits)

Opting to receive a CSI for their triggering finger

Disqualifiers

Decline to obtain a CSI for trigger finger management

Receiving multiple CSI for trigger finger management at the appointment

Past CSI and/or surgery to the digit involved

Unable to communicate in English

Trial design

Design model

Parallel

Treatments tested in this trial

  • Dorsal webspace combined corticosteroid and anesthetic injection

    Procedure/Surgery

    The dorsal webspace injection consists of a 1cc mixture of 0.5cc triamcinolone (Kenalog) 10mg/mL and 0.5cc 1% lidocaine for analgesic purposes.

  • Palmar combined corticosteroid and anesthetic injection

    Procedure/Surgery

    The palmar injection consists of a 1cc mixture of 0.5cc triamcinolone (Kenalog) 10mg/mL and 0.5cc 1% lidocaine for analgesic purposes.

Treatment groups

60 Participants
are divided into 2 treatment groups
Group A: Dorsal Webspace ApproachExperimental treatment 1 intervention
Group B: Palmar ApproachActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

Visual Analogue Scale (VAS) - Pain

100mm mechanical rating scale for pain, ranging from 0mm ("no pain") to 100mm ("pain as bad as it could be"); higher scores indicate a worse outcome.

Time frame
measured at 0 hours, 4 hours, and 24 hours post-injection
2

Numerical Rating Scale (NRS) - Pain

11-point numerical rating scale for pain, ranging from 0 (no pain) to 10 (worst pain ever possible); higher scores indicate a worse outcome.

Time frame
measured at 0 hours, 4 hours, and 24 hours post-injection
3

Short-Form McGill Pain Questionnaire (SFMPQ) - Present Pain Intensity (PPI)

5-point combined numerical-word rating scale for pain, ranging from 1 (mild) to 5 (excruciating); higher scores indicate a worse outcome.

Time frame
measured at 0 hours, 4 hours, and 24 hours post-injection

Secondary outcomes

1

Sensory Assessment - Light Touch

Semmes-Weinstein 2.0g monofilament test as threshold of sensory impairment

Time frame
measured at 0 hours post-injection
2

Sensory Assessment - Pain

Pinprick pain sensation with an 18-gauge sharp needle tip

Time frame
measured at 0 hours post-injection

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Kevin Zuo

Lead sponsor

University Health Network, Toronto

Sponsor institution